Reaction
Vitreous Detachment reporting signals
As of the last recalculation, Vitreous Detachment appears in 2,122 FAERS reports alongside 31 co-occurring drug terms. The strongest observed disproportionality signal is RANIBIZUMAB (PRR 52.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ranibizumab | 134 | 52.8 | 53.0 |
| Aflibercept | 78 | 25.4 | 25.5 |
| Carboxymethylcellulose Sodium | 12 | 12.6 | 12.6 |
| Brimonidine Tartrate | 22 | 12.2 | 12.2 |
| Prednisolone Acetate | 12 | 11.4 | 11.4 |
| Faricimab | 8 | 9.7 | 9.7 |
| Bevacizumab | 110 | 9.1 | 9.1 |
| Anastrozole | 30 | 8.1 | 8.1 |
| Raloxifene Hydrochloride | 12 | 8.1 | 8.1 |
| Brinzolamide | 7 | 7.9 | 7.9 |
| Timolol Maleate | 7 | 7.0 | 7.0 |
| Letrozole | 42 | 6.8 | 6.8 |
| Timolol | 8 | 6.5 | 6.5 |
| Letrozole Tablets | 28 | 5.8 | 5.8 |
| Botulinum Toxin Type A | 7 | 5.5 | 5.5 |
| Latanoprost | 27 | 5.3 | 5.3 |
| Bimatoprost | 15 | 5.1 | 5.1 |
| Encorafenib | 5 | 5.0 | 5.0 |
| Amphetamine | 4 | 4.7 | 4.8 |
| Dabrafenib | 10 | 4.7 | 4.7 |
| Trametinib | 11 | 4.5 | 4.5 |
| Eptinezumab-Jjmr | 4 | 4.3 | 4.3 |
| Crizotinib | 5 | 3.9 | 3.9 |
| Inclisiran | 3 | 3.7 | 3.7 |
| Oral Semaglutide | 25 | 3.4 | 3.4 |
| Siponimod | 3 | 3.3 | 3.3 |
| Vemurafenib | 4 | 3.3 | 3.3 |
| Peginterferon Beta-1A | 4 | 3.0 | 3.0 |
| Lifitegrast | 4 | 2.4 | 2.4 |
| Abaloparatide | 7 | 2.3 | 2.3 |
| Tirzepatide | 27 | 1.6 | 1.6 |